614 related articles for article (PubMed ID: 25330017)
1. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
6. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
[TBL] [Abstract][Full Text] [Related]
7. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
8. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
9. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
Ling W; Casadonte P; Bigelow G; Kampman KM; Patkar A; Bailey GL; Rosenthal RN; Beebe KL
JAMA; 2010 Oct; 304(14):1576-83. PubMed ID: 20940383
[TBL] [Abstract][Full Text] [Related]
11. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
[TBL] [Abstract][Full Text] [Related]
12. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
13. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
[TBL] [Abstract][Full Text] [Related]
14. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine tapering schedule and illicit opioid use.
Ling W; Hillhouse M; Domier C; Doraimani G; Hunter J; Thomas C; Jenkins J; Hasson A; Annon J; Saxon A; Selzer J; Boverman J; Bilangi R
Addiction; 2009 Feb; 104(2):256-65. PubMed ID: 19149822
[TBL] [Abstract][Full Text] [Related]
16. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
[TBL] [Abstract][Full Text] [Related]
17. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
19. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.
Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W
J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.
Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E
Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]